Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leitengshu (T8) for chronic abnormal immune activation in HIV patients – randomized double-blind phase II trial
CTR20191397Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxytriptolide in human immunodeficiency virus infection (HIV), Immunological non-response (INR), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jul 2019; status: completed.
02
Drugs
hydroxytriptolide
03
Conditions
human immunodeficiency virus infection (HIV)Immunological non-response (INR)
Beyond the preview
Go deeper on CTR20191397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191397.